Our findings align with previous studies on head and neck cancer, demonstrating that patients who achieved remission following anti-PD-1 monoclonal antibody therapy exhibited a significant increase in CD103+CD8+ T cells in their pretreatment biopsy tissues compared to those who did not achieve remission (30). This evidence concerns the gene PDCD1 and head and neck cancer.